1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Gilead’s Magrolimab Hit With Third Clinical Hold, This Time In AML

 
• By Ayisha Sharma

Gilead’s novel immune checkpoint inhibitor candidate, magrolimab, has been placed on a partial clinical hold by the US Food and Drug Administration in acute myeloid leukemia, adding to a spate of recent setbacks for the therapy that are chipping away at investor confidence.  

silhouette of man trying to hold up row of dominoes falling down
Magrolimab Could Succeed In AML Despite The Hold • Source: Shutterstock
Key Takeaways:

  • The hold stops new patients enrolling into Gilead’s ENHANCE-2 and ENHANCE-3 trials in AML.

  • No reason was provided but for previous holds, the firm cited suspected serious adverse reactions in the treatment arm, likely cytopenias.

  • AML has become a key indication for magrolimab after a pivotal MDS trial was discontinued last month.

Gilead Sciences, Inc.’s first-in-class immunotherapy candidate, magrolimab, has been hit with a partial clinical hold from the US Food and Drug Administration in acute myeloid leukemia (AML), less than...

Magrolimab is designed to block the inhibitory CD47-signal regulatory protein interaction (SIRPα), impeding the 'don’t eat me' signal of cancer cells and enabling macrophages and other phagocytes to identify and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

More from R&D

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.